Neupro(rotigotine)
Neupro (rotigotine) is a small molecule pharmaceutical. Rotigotine was first approved as Neupro on 2006-02-15. It is used to treat parkinson disease and restless legs syndrome in the USA. It has been approved in Europe to treat parkinson disease and restless legs syndrome. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target D(1A) dopamine receptor, D(4) dopamine receptor, D(3) dopamine receptor, and D(1B) dopamine receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Neupro
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| neupro | New Drug Application | 2024-09-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parkinson disease | EFO_0002508 | D010300 | G20 |
| restless legs syndrome | EFO_0004270 | D012148 | G25.81 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
108 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 15 | 9 | 25 | 10 | 9 | 66 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | 7 | 10 | 5 | 2 | 24 |
| Syndrome | D013577 | — | — | — | 8 | 10 | 4 | 2 | 24 |
| Psychomotor agitation | D011595 | — | — | — | 7 | 10 | 4 | 2 | 23 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | 1 | — | 2 |
| Hypokinesia | D018476 | — | — | — | — | — | 1 | 1 | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | 1 | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | 1 | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | 1 | — | 1 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | 1 | — | — | 2 |
| Sleep wake disorders | D012893 | — | G47 | — | — | 2 | — | — | 2 |
| Parasomnias | D020447 | — | G47.5 | — | — | 2 | — | — | 2 |
| Apathy | D057565 | HP_0000741 | — | — | — | 1 | — | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 2 | — | — | — | 2 |
| Postoperative pain | D010149 | — | G89.18 | — | 1 | — | — | — | 1 |
| Perceptual disorders | D010468 | — | R41.4 | — | 1 | — | — | — | 1 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | 1 | — | — | — | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | — | — | — | 1 |
| Neurologic manifestations | D009461 | — | — | — | 1 | — | — | — | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | 1 | — | — | — | 1 |
| Communication disorders | D003147 | — | F80.9 | — | 1 | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | — | — | — | 1 |
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | — | 1 | — | — | — | 1 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | — | — | — | — | 9 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rotigotine |
| INN | rotigotine |
| Description | 6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol is a member of tetralins. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1 |
Identifiers
| PDB | — |
| CAS-ID | 99755-59-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1303 |
| ChEBI ID | — |
| PubChem CID | 57537 |
| DrugBank | DB05271 |
| UNII ID | 87T4T8BO2E (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,109 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,795 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use